AnaptysBio: Upside Constrained By Undifferentiated Data, Legal Uncertainties

High Alpha Professor246 FollowersFollow5ShareSavePlay(18min)CommentsSummaryAnaptysBio is splitting into a high-margin royalty company and a pipeline-focused biopharma, each with distinct valuation drivers.The royalty business, anchored by Jemperli royalties and minimal expenses, offers stable cash flows but faces risk from a pending lawsuit and Sagard repayment.First Tracks, the pipeline entity, is led by rosnilimab—a T-cell depleter with strong translational data but uncertain commercial differentiation in a crowded RA market.Despite positive phase 2 data, dilution risk and lack of clear superiority lead me to rate ANAB as a Hold at current valuation. Dougal Waters/DigitalVision via Getty Images Introduction Given its planned separation into a royalty company and another with a development-stage pipeline, AnaptysBio (ANAB) now has to be valued as two different businesses. The royalty business, backed by the billion-dollar blockbusterThis article was written byHigh Alpha Professor246 FollowersFollowDubai-based investor focused on building a resilient, income-generating portfolio with a long-term growth mindset. My approach is primarily long-only, blending dividend-paying equities, REITs, and other income strategies with selective growth opportunities. I believe in disciplined, fundamentals-driven investing, prioritizing capital preservation while compounding returns over time. Originally from India.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.